Abstract
The EGADi project aims to identify innovative early biomarkers and therapeutic targets for Alzheimer's disease (AD) by investigating molecular mechanisms underlying its pathogenesis. Using advanced molecular biology techniques, EGADi will analyze biomarkers in plasma, cerebrospinal fluid, and extracellular vesicles (EVs) from healthy controls, prodromal subjects, and AD patients. The project will develop in vitro models derived from patient fibroblasts to study intercellular communication mediated by EVs. Expected outcomes include a comprehensive biomarker profile for early AD diagnosis and identification of new pharmacological targets, enabling improved diagnostic approaches and innovative treatments, ultimately promoting healthy aging and reducing the social burden of AD.
Project details
Unibo Team Leader: Patrizia Hrelia
Unibo involved Department/s:
Dipartimento di Farmacia e Biotecnologie
Coordinator:
ALMA MATER STUDIORUM - Università di Bologna(Italy)
Total Eu Contribution: Euro (EUR) 300.000,00
Total Unibo Contribution: Euro (EUR) 120.000,00
Project Duration in months: 24
Start Date:
30/11/2023
End Date:
28/02/2026
